Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices

Joyce S. Hui-Yuen, Arthi Reddy, Jennifer Taylor, Xiaoqing Li, Andrew H. Eichenfield, Liza M. Bermudez, Amy J. Starr, Lisa F. Imundo, Jill Buyon, Richard A. Furie, Diane L. Kamen, Susan Manzi, Michelle Petri, Rosalind Ramsey-Goldman, Ronald F. Van Vollenhoven, Daniel J. Wallace, Anca Askanase

Research output: Contribution to journalArticle

Abstract

Objective. To evaluate the use and efficacy of belimumab in academic practices. Belimumab is a human monoclonal antibody that inhibits soluble B lymphocyte stimulator and has been approved for the treatment of adults with systemic lupus erythematosus (SLE). Methods. Invitations to participate and complete a 1-page questionnaire for each patient prescribed belimumab were sent to 16 physicians experienced in SLE phase III clinical trials. The outcome was defined as the physician's impression of improvement in the initial manifestation(s) being treated without worsening in other organ systems. Results. Of 195 patients treated with belimumab at 10 academic centers, 96% were taking background medications for SLE at initiation of belimumab, with 74% taking corticosteroids. The main indications for initiation of belimumab were arthritis, rash, and/or worsening serologic activity, with 30% of patients unable to taper corticosteroids. Of the 120 patients taking belimumab for at least 6 months, 51% responded clinically and 67% had ≥ 25% improvement in laboratory values. While numbers are limited, black patients showed improvement at 6 months. In a subset of 39 patients with childhood-onset SLE, 65% responded favorably at 6 months, and 35% discontinued corticosteroids. Conclusion. Our data demonstrate favorable clinical and laboratory outcomes in patients with SLE at 6 months across all racial and ethnic groups, with similar improvement seen among patients with childhood-onset SLE.

Original languageEnglish (US)
Pages (from-to)2288-2295
Number of pages8
JournalJournal of Rheumatology
Volume42
Issue number12
DOIs
StatePublished - Dec 1 2015

Fingerprint

Systemic Lupus Erythematosus
Safety
Adrenal Cortex Hormones
B-Cell Activating Factor
Physicians
Phase III Clinical Trials
belimumab
Exanthema
Ethnic Groups
Arthritis
Monoclonal Antibodies

Keywords

  • Belimumab
  • Childhood-onset SLE
  • SLE treatment
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Hui-Yuen, J. S., Reddy, A., Taylor, J., Li, X., Eichenfield, A. H., Bermudez, L. M., ... Askanase, A. (2015). Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices. Journal of Rheumatology, 42(12), 2288-2295. https://doi.org/10.3899/jrheum.150470

Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices. / Hui-Yuen, Joyce S.; Reddy, Arthi; Taylor, Jennifer; Li, Xiaoqing; Eichenfield, Andrew H.; Bermudez, Liza M.; Starr, Amy J.; Imundo, Lisa F.; Buyon, Jill; Furie, Richard A.; Kamen, Diane L.; Manzi, Susan; Petri, Michelle; Ramsey-Goldman, Rosalind; Van Vollenhoven, Ronald F.; Wallace, Daniel J.; Askanase, Anca.

In: Journal of Rheumatology, Vol. 42, No. 12, 01.12.2015, p. 2288-2295.

Research output: Contribution to journalArticle

Hui-Yuen, JS, Reddy, A, Taylor, J, Li, X, Eichenfield, AH, Bermudez, LM, Starr, AJ, Imundo, LF, Buyon, J, Furie, RA, Kamen, DL, Manzi, S, Petri, M, Ramsey-Goldman, R, Van Vollenhoven, RF, Wallace, DJ & Askanase, A 2015, 'Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices', Journal of Rheumatology, vol. 42, no. 12, pp. 2288-2295. https://doi.org/10.3899/jrheum.150470
Hui-Yuen, Joyce S. ; Reddy, Arthi ; Taylor, Jennifer ; Li, Xiaoqing ; Eichenfield, Andrew H. ; Bermudez, Liza M. ; Starr, Amy J. ; Imundo, Lisa F. ; Buyon, Jill ; Furie, Richard A. ; Kamen, Diane L. ; Manzi, Susan ; Petri, Michelle ; Ramsey-Goldman, Rosalind ; Van Vollenhoven, Ronald F. ; Wallace, Daniel J. ; Askanase, Anca. / Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices. In: Journal of Rheumatology. 2015 ; Vol. 42, No. 12. pp. 2288-2295.
@article{b93927d98c6f4de2a9ed2ce8dbbf28e8,
title = "Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices",
abstract = "Objective. To evaluate the use and efficacy of belimumab in academic practices. Belimumab is a human monoclonal antibody that inhibits soluble B lymphocyte stimulator and has been approved for the treatment of adults with systemic lupus erythematosus (SLE). Methods. Invitations to participate and complete a 1-page questionnaire for each patient prescribed belimumab were sent to 16 physicians experienced in SLE phase III clinical trials. The outcome was defined as the physician's impression of improvement in the initial manifestation(s) being treated without worsening in other organ systems. Results. Of 195 patients treated with belimumab at 10 academic centers, 96{\%} were taking background medications for SLE at initiation of belimumab, with 74{\%} taking corticosteroids. The main indications for initiation of belimumab were arthritis, rash, and/or worsening serologic activity, with 30{\%} of patients unable to taper corticosteroids. Of the 120 patients taking belimumab for at least 6 months, 51{\%} responded clinically and 67{\%} had ≥ 25{\%} improvement in laboratory values. While numbers are limited, black patients showed improvement at 6 months. In a subset of 39 patients with childhood-onset SLE, 65{\%} responded favorably at 6 months, and 35{\%} discontinued corticosteroids. Conclusion. Our data demonstrate favorable clinical and laboratory outcomes in patients with SLE at 6 months across all racial and ethnic groups, with similar improvement seen among patients with childhood-onset SLE.",
keywords = "Belimumab, Childhood-onset SLE, SLE treatment, Systemic lupus erythematosus",
author = "Hui-Yuen, {Joyce S.} and Arthi Reddy and Jennifer Taylor and Xiaoqing Li and Eichenfield, {Andrew H.} and Bermudez, {Liza M.} and Starr, {Amy J.} and Imundo, {Lisa F.} and Jill Buyon and Furie, {Richard A.} and Kamen, {Diane L.} and Susan Manzi and Michelle Petri and Rosalind Ramsey-Goldman and {Van Vollenhoven}, {Ronald F.} and Wallace, {Daniel J.} and Anca Askanase",
year = "2015",
month = "12",
day = "1",
doi = "10.3899/jrheum.150470",
language = "English (US)",
volume = "42",
pages = "2288--2295",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "12",

}

TY - JOUR

T1 - Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices

AU - Hui-Yuen, Joyce S.

AU - Reddy, Arthi

AU - Taylor, Jennifer

AU - Li, Xiaoqing

AU - Eichenfield, Andrew H.

AU - Bermudez, Liza M.

AU - Starr, Amy J.

AU - Imundo, Lisa F.

AU - Buyon, Jill

AU - Furie, Richard A.

AU - Kamen, Diane L.

AU - Manzi, Susan

AU - Petri, Michelle

AU - Ramsey-Goldman, Rosalind

AU - Van Vollenhoven, Ronald F.

AU - Wallace, Daniel J.

AU - Askanase, Anca

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Objective. To evaluate the use and efficacy of belimumab in academic practices. Belimumab is a human monoclonal antibody that inhibits soluble B lymphocyte stimulator and has been approved for the treatment of adults with systemic lupus erythematosus (SLE). Methods. Invitations to participate and complete a 1-page questionnaire for each patient prescribed belimumab were sent to 16 physicians experienced in SLE phase III clinical trials. The outcome was defined as the physician's impression of improvement in the initial manifestation(s) being treated without worsening in other organ systems. Results. Of 195 patients treated with belimumab at 10 academic centers, 96% were taking background medications for SLE at initiation of belimumab, with 74% taking corticosteroids. The main indications for initiation of belimumab were arthritis, rash, and/or worsening serologic activity, with 30% of patients unable to taper corticosteroids. Of the 120 patients taking belimumab for at least 6 months, 51% responded clinically and 67% had ≥ 25% improvement in laboratory values. While numbers are limited, black patients showed improvement at 6 months. In a subset of 39 patients with childhood-onset SLE, 65% responded favorably at 6 months, and 35% discontinued corticosteroids. Conclusion. Our data demonstrate favorable clinical and laboratory outcomes in patients with SLE at 6 months across all racial and ethnic groups, with similar improvement seen among patients with childhood-onset SLE.

AB - Objective. To evaluate the use and efficacy of belimumab in academic practices. Belimumab is a human monoclonal antibody that inhibits soluble B lymphocyte stimulator and has been approved for the treatment of adults with systemic lupus erythematosus (SLE). Methods. Invitations to participate and complete a 1-page questionnaire for each patient prescribed belimumab were sent to 16 physicians experienced in SLE phase III clinical trials. The outcome was defined as the physician's impression of improvement in the initial manifestation(s) being treated without worsening in other organ systems. Results. Of 195 patients treated with belimumab at 10 academic centers, 96% were taking background medications for SLE at initiation of belimumab, with 74% taking corticosteroids. The main indications for initiation of belimumab were arthritis, rash, and/or worsening serologic activity, with 30% of patients unable to taper corticosteroids. Of the 120 patients taking belimumab for at least 6 months, 51% responded clinically and 67% had ≥ 25% improvement in laboratory values. While numbers are limited, black patients showed improvement at 6 months. In a subset of 39 patients with childhood-onset SLE, 65% responded favorably at 6 months, and 35% discontinued corticosteroids. Conclusion. Our data demonstrate favorable clinical and laboratory outcomes in patients with SLE at 6 months across all racial and ethnic groups, with similar improvement seen among patients with childhood-onset SLE.

KW - Belimumab

KW - Childhood-onset SLE

KW - SLE treatment

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=84948799807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948799807&partnerID=8YFLogxK

U2 - 10.3899/jrheum.150470

DO - 10.3899/jrheum.150470

M3 - Article

VL - 42

SP - 2288

EP - 2295

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 12

ER -